Trial Profile
An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Vididencel (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms ADVANCE II
- Sponsors Mendus
- 14 Feb 2024 According to a Mendus media release, based on the ADVANCE II data and data from the first stage of the CADENCE trial, Mendus expects to be in a position to engage in a global registration path for vididencel in 2025.
- 22 Dec 2023 Results presented in a Mendus media release.
- 12 Dec 2023 Results (N=20) presented at the 65th American Society of Hematology Annual Meeting and Exposition